Press Releases Spruce Biosciences, Inc.

Equities

SPRB

US85209E1091

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
0.708 ^USD	-0.28%		+0.97%	-75.84%

Mar. 15	North American Morning Briefing : Inflation -2-	DJ
Mar. 14	Top Midday Decliners	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting	Apr. 30	BU
Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting	Apr. 22	BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB	Apr. 04	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB	Mar. 27	PR
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	Mar. 21	BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB	Mar. 19	PR
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	Mar. 14	BU
Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates	Mar. 13	BU
Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH	Mar. 13	BU
Spruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Jan. 30	BU
Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia	Jan. 22	BU
SPRUCE BIOSCIENCES REPORTS BASELINE CHARACTERISTICS FROM CAHMELIA-203 AND CAHMELIA-204 STUDIES IN ADULT CLASSIC CAH	Jan. 08	AQ
Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH	Jan. 05	BU
Spruce Biosciences Provides Clinical Program Updates and Outlook for 2024	Jan. 04	BU
Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates	Nov. 13	BU
Spruce Biosciences to Participate in the Jefferies London Healthcare Conference	Nov. 02	BU
Spruce Biosciences Completes Target Enrollment of CAHmelia-203 Study in Adult Classic Congenital Adrenal Hyperplasia	23-10-18	BU
Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference	23-08-28	BU
Spruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates	23-08-14	BU
SPRUCE BIOSCIENCES ANNOUNCES ACCEPTANCE OF ABSTRACT FOR PRESENTATION AT THE ANNUAL MEETING OF THE ENDOCRINE SOCIETY	23-06-13	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Spruce Biosciences, Inc.

Equities

SPRB

US85209E1091

Press Releases

Filters